| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vivo |
F8-IL-4 (100 μg per mouse; intraperitoneal injection; days 1, 4 and 7 after disease onset; day 10) alleviated collagen-induced arthritis in DBA/1 mice by modulating T cell subsets and macrophage polarization; when used in combination with dexamethasone, it produced synergistic and durable therapeutic effects and prevented relapse of arthritis after drug withdrawal by maintaining anti-inflammatory cell phenotype and cytokine profile [1].
|
|---|---|
| Animal Protocol |
Animal/Disease Models:DBA/1 (10-12 week old males; collagen-induced arthritis model) [1]
Doses: 100 μg per mouse Route of Administration: Intraperitoneal injection; days 1, 4 and 7 after disease onset; for 10 days Experimental Results: Arthritis score decreased, IL-4 levels in joints and serum increased, IL-1β, IL-17A, IL-6 and GM-CSF levels in paws decreased, and TNF-α levels in paws increased. The total number and percentage of IL-4-secreting T_H2 cells in joints increased significantly, while the number of IL-17A-secreting CD4+ and TCRγδ T cells decreased significantly. The proportion of CD206+ macrophages in paws increased, while the proportion of macrophages expressing MHC class II molecules in paws decreased. The expression of IL-12b (p40) mRNA in spleen decreased. It produces a synergistic therapeutic effect when used in combination with dexamethasone. When used in combination with dexamethasone, it significantly increases serum IL-10 levels. When used in combination with dexamethasone, it significantly reduces the levels of IL-1β, IL-6, GM-CSF, and IL-12p70 in the claws. It significantly increases the proportion of CD25+FoxP3+ Treg cells in CD4+ T cells in the joints and significantly reduces the T_H17/Treg cell ratio. It significantly increases the proportion of CD206+ macrophages in the claws and significantly reduces the proportion of total macrophages and macrophages highly expressing MHC class II molecules in the claws. It significantly increases the expression of arginase 1, IL-10, and Chil3 (Ym1) mRNA in the spleen and significantly reduces the expression of Nos2 and Il12b (p40) mRNA. It significantly reduces the total number of cells, T_H17 cells, IL-17A+ TCRγδ T cells, and neutrophils in the claws. It significantly reduced the levels of IL-17A, IL-1β, and IL-12 in the claw and significantly increased the serum IL-10 level. It significantly increased the proportion of CD206+ macrophages in the claw and decreased the proportion of MHC class II positive macrophages. It significantly increased the expression of arginase 1 and IL-10 mRNA in the spleen and decreased the expression of IL-12b (p40) mRNA. |
| References |
| Appearance |
Typically exists as solids at room temperature
|
|---|---|
| SMILES |
[F8-IL-4]
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
